August 4, 2025

Figure S4 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis

Key Points

MAIN FINDING: The humanized CD36-blocking antibody effectively enhances antitumor immunity against liver cancer.
KEY EVIDENCE: The MYCOE/CTNNB1N90 mouse model demonstrated significant immune response upon treatment with CD36 antibody.
APPROACH: The study characterized liver cancer progression in a lipid-rich environment using a specific mouse model.
SIGNIFICANCE: This research highlights a potential new strategy to improve treatment outcomes for liver cancer patients.

Abstract

Characterization of the progression and immune profile of the MYCOE /CTNNB1N90 liver cancer mouse model in the context of lipid-rich condition.

Bookmark

Cite This Study

Tzeng et al. (Mon,) studied this question.

synapsesocial.com/papers/689a0f86e6551bb0af8d0929 https://doi.org/https://doi.org/10.1158/2159-8290.29819662

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Figure S2 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis2025